C11orf52 Inhibitors
Staurosporine and other kinase inhibitors, such as PD98059 and U0126, target the phosphorylation processes, which are crucial for the activation of many proteins within the cell. If C11orf52 is activated or stabilized by phosphorylation, these inhibitors could lead to its functional inhibition. By targeting key kinases within the MAPK/ERK pathway, these compounds can disrupt the signaling cascades, possibly affecting proteins like C11orf52 that may be dependent on this pathway.
Compounds such as LY294002 and Wortmannin specifically inhibit the PI3K/Akt pathway, which is a critical signaling pathway involved in controlling cell survival and metabolism. If C11orf52 functions within this pathway or is regulated by it, inhibition of PI3K can prevent the downstream activation of Akt, leading to an indirect decrease in C11orf52 activity. Similarly, the mTOR inhibitor rapamycin can lead to reduced protein synthesis of proteins that may be associated with C11orf52, thereby influencing its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent protein kinase inhibitor known to broadly target protein kinases, which can lead to the inhibition of phosphorylation events necessary for C11orf52 activation or stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can downregulate PI3K/Akt signaling, potentially impacting C11orf52 if it's involved in this pathway by inhibiting downstream effects that might stabilize or activate C11orf52. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which can inhibit the mTOR pathway, potentially reducing protein synthesis of proteins downstream or associated with C11orf52, thus indirectly inhibiting its functional activity. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that inhibits calcineurin, thereby potentially impacting the NFAT pathway which could be integral to the functional activity of C11orf52. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that can inhibit the MAPK/ERK pathway, possibly leading to decreased functional activity of C11orf52 if it relies on this pathway for activation or stability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that may lead to reduced activity of C11orf52 if it is modulated by or dependent on the p38 MAPK signaling for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the JNK signaling pathway which could decrease C11orf52 activity if C11orf52 is regulated by JNK-mediated signaling events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that can also downregulate the MAPK/ERK pathway, potentially affecting C11orf52 activity by the same mechanism as PD98059. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An inhibitor of histone deacetylases (HDACs) which could alter chromatin structure and thus indirectly affect the activity of C11orf52 by changing the expression of genes that regulate C11orf52 or its pathway components. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can lead to accumulation of misfolded proteins, potentially affecting C11orf52 by inhibiting its degradation pathway and leading to cellular stress that indirectly reduces its activity. | ||||||